share_log

Candel Therapeutics Presents Preclinical Data From Its EnLIGHTEN Discovery Platform at SITC; The First Experimental Agent Is Alpha-201-Macro1, An Investigational Viral Immunotherapy Designed To Activate Innate Immune Surveillance

Candel Therapeutics Presents Preclinical Data From Its EnLIGHTEN Discovery Platform at SITC; The First Experimental Agent Is Alpha-201-Macro1, An Investigational Viral Immunotherapy Designed To Activate Innate Immune Surveillance

Candel Therapeutics公布了来自SITC的Enlighten发现平台的临床前数据;第一种实验药物是Alpha-201-Macro1,这是一种旨在激活先天免疫监测的在研病毒免疫疗法
Benzinga ·  2023/11/06 08:31

Candel Therapeutics Presents Preclinical Data From Its EnLIGHTEN Discovery Platform at SITC; The First Experimental Agent Is Alpha-201-Macro1, An Investigational Viral Immunotherapy Designed To Activate Innate Immune Surveillance

Candel Therapeutics公布了来自SITC的Enlighten发现平台的临床前数据;第一种实验药物是Alpha-201-Macro1,这是一种旨在激活先天免疫监测的在研病毒免疫疗法

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发